Veno-occlusive disease of the liver (VOD) is an uncommon, early complication of hematopoietic cell transplantation (HCT) that is associated with significant mortality.
Clear all selections
Age -- < 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
Karnofsky/Lansky Score -- 0 to 80 90 to 100
Sirolimus Use -- Yes No
Hepatitis B/C Status -- B & C Negative B & C Positive B Positive (C Negative) C Positive (B Negative)
Conditioning Regimen -- No Regimen or NST MAC-Chemo: Bu/Cy With PK MAC-Chemo: Bu/Cy No PK MAC-Chemo: Bu/Cy/Others With PK MAC-Chemo: Bu/Cy/Others No PK MAC-Chemo: Bu/Flu With PK MAC-Chemo: Bu/Flu No PK MAC-Chemo: Bu/Flu/Others With PK MAC-Chemo: Bu/Flu/Others No PK MAC-Chemo: Bu ± Others With PK MAC-Chemo: Bu ± Others No PK MAC-Chemo: Bu/Mel ± Others With PK MAC-Chemo: Bu/Mel ± Other No PK MAC-Chemo: Thio ± Others (Non-Bu) MAC-TBI: <=12 Gy TBI/Cy MAC-TBI: >12 Gy TBI/Cy MAC-TBI: <=12 Gy TBI/Cy/Others MAC-TBI: >12 Gy TBI/Cy/Others MAC-TBI: <=12 Gy TBI ± Others MAC-TBI: >12 Gy TBI ± Others RIC-Chemo: Bu ± Others RIC-Chemo: Mel ± Others or BEAM/CBV Like RIC-TBI
Disease -- ALL; Early/Missing ALL; Intermediate ALL; Advanced AML; Early/Intermediate AML; Advanced/Missing CML; Early/Intermediate CML; Advanced Other Leukemias NHL / Hodgkin Disease; PIF Resistant NHL / Hodgkin Disease; PIF/Rel Sensitive, CR, or Untreated NHL / Hodgkin Disease; Rel Resistant Myelodysplastic Syndrome; Early/Advanced Aplastic Anemia/Abnormalities of Erythrocytes Myeloproliferative Syndromes Severe Combined Immunodeficiency Inherited Problems of Metabolism Histiocytic Disorders Multiple Myeloma
Probability of developing VOD by day 100:
*Patients who received syngeneic twin transplants, did not provide signed informed consent, had inadequate follow-up, or received defibrotide as prophylaxis were not included in this study.